Intra-Cellular Therapies (ITCI) News Today $82.72 -2.13 (-2.51%) (As of 09:51 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Barclays PLC Increases Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Barclays PLC raised its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 282.0% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 34,453 shares of the biopharmaceutical company's stock after buying an additional 25,435December 26, 2024 | marketbeat.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Acquired by Principal Financial Group Inc.Principal Financial Group Inc. grew its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 3.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 597,713 shares of the biopharmaceutical company's stock after purchasinDecember 23, 2024 | marketbeat.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives Consensus Rating of "Moderate Buy" from BrokeragesDecember 20, 2024 | americanbankingnews.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives Average Rating of "Moderate Buy" from BrokeragesShares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Get Free Report) have been given an average rating of "Moderate Buy" by the thirteen research firms that are currently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and eleven haveDecember 20, 2024 | marketbeat.comGeode Capital Management LLC Boosts Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Geode Capital Management LLC grew its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 1.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,708,301 shares of the biopharmaceuticalDecember 18, 2024 | marketbeat.comFranklin Resources Inc. Acquires 155,655 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Franklin Resources Inc. boosted its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 9.7% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,753,286 shares of the biopharmaceutical company's stock afteDecember 16, 2024 | marketbeat.comState Street Corp Buys 56,664 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)State Street Corp increased its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 3.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,858,915 shares of the biopharmaceutDecember 15, 2024 | marketbeat.comY Intercept Hong Kong Ltd Sells 62,349 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Y Intercept Hong Kong Ltd decreased its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 82.0% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,651 shares of the biopharmaceutical company's stocDecember 13, 2024 | marketbeat.comIntra-Cellular presents data from CAPLYTA adjunctive MDD Phase 3 programDecember 11, 2024 | markets.businessinsider.comIntra-Cellular Therapies Inc (ITCI) Presents Promising Data on CAPLYTA for Major Depressive DisorderDecember 11, 2024 | gurufocus.comIntra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual MeetingDecember 11, 2024 | globenewswire.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock Position Lowered by Wellington Management Group LLPWellington Management Group LLP lessened its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 18.8% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,017,647 shares of the biopharmaceutical company's stoDecember 11, 2024 | marketbeat.comPoint72 Asset Management L.P. Has $8.77 Million Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Point72 Asset Management L.P. lowered its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 78.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 119,862 shares of the biopharmaceutical compaDecember 8, 2024 | marketbeat.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by BNP Paribas Financial MarketsBNP Paribas Financial Markets lessened its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 49.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 24,923 shares of the biopharmaceutical company's stock afteDecember 8, 2024 | marketbeat.comInsider Selling: Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) CEO Sells 51,000 Shares of StockIntra-Cellular Therapies, Inc. (NASDAQ:ITCI - Get Free Report) CEO Sharon Mates sold 51,000 shares of the stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total value of $4,375,800.00. Following the completion of the transaction, the chief executive officer now owns 1,070,329 shares of the company's stock, valued at $91,834,228.20. This trade represents a 4.55 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.December 6, 2024 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 11,104 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 3.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 323,December 6, 2024 | marketbeat.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Bought by Parkman Healthcare Partners LLCParkman Healthcare Partners LLC increased its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 30.6% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 241,575 shares of the biopharmDecember 4, 2024 | marketbeat.comHighVista Strategies LLC Lowers Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)HighVista Strategies LLC lessened its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 69.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,496 shares of the biopharmaceutical compaDecember 4, 2024 | marketbeat.comErste Asset Management GmbH Buys Shares of 23,400 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Erste Asset Management GmbH purchased a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 23,400 shares of the biopharmaceutical companDecember 4, 2024 | marketbeat.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Bank of Montreal CanBank of Montreal Can lessened its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 78.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 64,198 shares of the biopharmaceuticaDecember 4, 2024 | marketbeat.comIntra-Cellular recently submitted a sNDA to the U.S. FDA for CAPLYTA for MDDDecember 3, 2024 | markets.businessinsider.comIntra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive TherapyDecember 3, 2024 | globenewswire.comPoint72 Hong Kong Ltd Decreases Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Point72 Hong Kong Ltd reduced its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 85.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,293 shares of the biopharmaceutiDecember 3, 2024 | marketbeat.comBellevue Group AG Has $181.87 Million Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Bellevue Group AG increased its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 0.6% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,485,627 shares of the biopharmaceutical company's stockDecember 1, 2024 | marketbeat.comEdgestream Partners L.P. Takes $4 Million Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Edgestream Partners L.P. bought a new stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 54,629 shares of the biopharmaceuticalDecember 1, 2024 | marketbeat.comPoint72 Europe London LLP Sells 12,915 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Point72 Europe London LLP trimmed its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 40.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 19,385 shares of the biopharmaceutical company'sDecember 1, 2024 | marketbeat.comCerity Partners LLC Has $3.23 Million Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Cerity Partners LLC increased its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 62.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 44,107 shares of the biopharmaceutical company's stock after buying an additional 17,December 1, 2024 | marketbeat.comVestal Point Capital LP Purchases New Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Vestal Point Capital LP acquired a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 30,000 shares of the biopharmaceutical company's sNovember 29, 2024 | marketbeat.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Position Trimmed by Suvretta Capital Management LLCSuvretta Capital Management LLC lowered its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 8.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,439,026 shares of the biopharmaceutNovember 29, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Sells 16,160 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Charles Schwab Investment Management Inc. trimmed its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 1.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 904,909 shares oNovember 29, 2024 | marketbeat.comFmr LLC Trims Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Fmr LLC lowered its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 1.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 11,121,652 shares of the biopharmaceutical company's stock after sellingNovember 28, 2024 | marketbeat.comCynosure Group LLC Raises Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Cynosure Group LLC increased its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 161.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,442 shares of the biopharmaceutNovember 27, 2024 | marketbeat.com17,099 Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Purchased by Connor Clark & Lunn Investment Management Ltd.Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 17,099 shares of the biopharNovember 27, 2024 | marketbeat.comAlgert Global LLC Sells 20,990 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Algert Global LLC lowered its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 31.6% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 45,350 shares of the biopharmaceutical company's stock after selling 20,990 shares durinNovember 26, 2024 | marketbeat.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Natixis Advisors LLCNatixis Advisors LLC cut its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 22.4% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 24,583 shares of the biopharmaceutical company's stock after selling 7,077 sNovember 26, 2024 | marketbeat.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Given Average Rating of "Moderate Buy" by AnalystsShares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Get Free Report) have been given a consensus rating of "Moderate Buy" by the thirteen brokerages that are currently covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and eleven haveNovember 25, 2024 | marketbeat.comWestfield Capital Management Co. LP Buys 116,494 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Westfield Capital Management Co. LP boosted its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 11.2% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,159,356 shares of the biopharmaceutical company's stock after acNovember 24, 2024 | marketbeat.comEagle Asset Management Inc. Boosts Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Eagle Asset Management Inc. grew its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 130.5% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 624,759 shares of the biopharmaceutical company's stock after buyinNovember 23, 2024 | marketbeat.comBNP PARIBAS ASSET MANAGEMENT Holding S.A. Purchases 109,892 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 31.9% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 454,538 shares of the biopharNovember 23, 2024 | marketbeat.comSwiss National Bank Acquires 13,900 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Swiss National Bank boosted its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 8.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 185,500 shares of the biopharmaceutical companyNovember 23, 2024 | marketbeat.comB. Metzler seel. Sohn & Co. Holding AG Takes $2.44 Million Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) during the third quarter, according to its most recent filing with the SEC. The firm acquired 33,291 shares of the biopharmaceutical company's stock, valued at approximately $2,November 22, 2024 | marketbeat.comIntra-Cellular Therapies to Participate in Three Upcoming Investor ConferencesNovember 19, 2024 | globenewswire.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Holdings Decreased by First Turn Management LLCFirst Turn Management LLC decreased its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 26.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 254,800 shares of tNovember 19, 2024 | marketbeat.comLMR Partners LLP Grows Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)LMR Partners LLP raised its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 96.2% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 31,177 shares of the biopharmaceutNovember 19, 2024 | marketbeat.comEntropy Technologies LP Acquires Shares of 7,116 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Entropy Technologies LP bought a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 7,116 shares of the biopharmaceuNovember 16, 2024 | marketbeat.comSimplify Asset Management Inc. Increases Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Simplify Asset Management Inc. raised its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 66.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 30,883 shares of the biopharmaceutNovember 15, 2024 | marketbeat.comInsider Selling: Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) President Sells 22,869 Shares of StockNovember 15, 2024 | insidertrades.comAigen Investment Management LP Increases Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Aigen Investment Management LP boosted its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 91.3% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 14,890 shares of the biopharmaceutical company's stock after buying an additNovember 13, 2024 | marketbeat.comIntra-Cellular Therapies (NASDAQ:ITCI) Sets New 1-Year High - Still a Buy?Intra-Cellular Therapies (NASDAQ:ITCI) Hits New 12-Month High - Should You Buy?November 11, 2024 | marketbeat.comLisanti Capital Growth LLC Has $4.25 Million Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Lisanti Capital Growth LLC trimmed its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 29.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 58,115 shares of the biopharmNovember 11, 2024 | marketbeat.com Get Intra-Cellular Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter. Email Address Kamala’s final humiliation (Ad)The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware of… yet have the potential to deliver colossal returns over the next four years. I’m not talking about Tesla, Palantir, or anything else you’ve heard parroted by the mainstream financial press. No. These are Trump’s Secret Stocks. It’s all waiting for you here. ITCI Media Mentions By Week ITCI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ITCI News Sentiment▼0.630.59▲Average Medical News Sentiment ITCI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ITCI Articles This Week▼27▲ITCI Articles Average Week Get Intra-Cellular Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BNTX News TEVA News BGNE News MRNA News VTRS News SMMT News GMAB News RDY News CTLT News SRPT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ITCI) was last updated on 12/30/2024 by MarketBeat.com Staff From Our PartnersGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored3 CENT Crypto to Explode December 16th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored>>>RE: Buy this Stock before Trump Takes Office!To make sure everyone has the opportunity to get in, closes for good at midnight on January 1st, we're lowerin...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intra-Cellular Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intra-Cellular Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
